XCUR | Exicure, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	N/A - N/A
52 Week Range	N/A - N/A
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	N/A
Average Volume	N/A
Shares Outstanding	N/A
Market Cap	N/A
Sector	Healthcare
Industry	Biotechnology
IPO Date	2018-05-22

Valuation
Profitability
Growth
Health
P/E Ratio	N/A
Forward P/E Ratio	N/A
EPS	N/A
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	5
Country	USA
Website	XCUR

Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

XCUR's peers: CLGN, LOGC, MRKR, IKNA, ENOB, ELYM, HCWB, ZIVO, RNXT, TPST, CBIO, SCPH, MIST, ONCY, MCRB, LIFE, LUMO, PTIX, PMVP, IMNN, CYCC, HSTO, DMAC, CVKD, TOVX

*Chart delayed

Analyzing fundamentals for XCUR we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see XCUR Fundamentals page.

Watching at XCUR technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on XCUR Technicals page.